Results 151 to 160 of about 53,090 (292)

Production system establishment and in vitro study of CD19/CD3ε bite antibody secreted from Pichia pastoris

Blinatumomab is an anti-cancer Bispecific T-cell Engager (BiTE) antibody drug approved by the Food and Drug Administration (FDA) for treating acute lymphoblastic leukemia (ALL).
Boram Kim, So Yeong Cheon, Chan Gil Kim, Kyu Tae Byun, Seung Hyeon Lee   +4 more
core   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. [PDF]

Mol Biomed
Zhang Z, Yang N, Zeng H, Chen Y, Lu H, Xu L, Wang Z, Wang G, Zhou L, Tong A.   +9 more
europepmc   +1 more source

Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance

, 1993
A portion of patients with acute myeloid leukemia also display surface antigens associated with lymphoid development (Ly+AML). The incidence of Ly+AML varies considerably between independent studies, both overall and with regard to individual antigens ...
Thiel, E., Drexler, H.G., Ludwig, W.D.
core  

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. [PDF]

Exp Hematol Oncol
Riet T, Lennartz S, Bösing N, Prinz LF, Dähn L, Scheid C, Hallek M, Chmielewski MM.   +7 more
europepmc   +1 more source

Inovação na oncologia com imunoterapia de células CAR-T CD19 para tratamento de leucemia linfoblástica aguda: uma revisão integrativa

Introdução: A Leucemia Linfoblástica Aguda é uma neoplasia cuja abordagem terapêutica convencional inclui quimioterapia e transplante de células hematopoiéticas.
Ferreira , Maria Luiza Garcia, Diniz, Giovana Alves, Ribeiro, Rebeca, Sales, Eliza Domingues Tran, Reis, Sabrina Thalita dos, Costa, Vitória Vitoriano da, Barros , Laura Valcante   +6 more
core   +1 more source

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

Allergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti, Chiara Vasco, Francesca Clemente, Paola Larghi, Sara Maioli, Edoardo Scarpa, Elena Carelli, Nadia Pulvirenti, Maria Lucia Sarnicola, Mariacristina Crosti, Manal Bel Imam, Willem van de Veen, Loris Rizzello, Sergio Abrignani, Lucia A. Baselli, Rosa Maria Dellepiane, Maria Carrabba, Giovanna Fabio, Jens Geginat   +18 more
wiley   +1 more source

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, EarlyView.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review. [PDF]

Front Oncol
Husodho GVP, Kumalasari ADA, Faiza AH, Limijadi EKS, Hendrianingtyas M.   +4 more
europepmc   +1 more source